BAY 2666605

Names

[ Name ]:
BAY 2666605

Biological Activity

[Description]:

BAY 2666605 is an orally active PDE3A and PDE3B inhibitor with IC50s of 87 nM and 50 nM, respectively. BAY 2666605 is a PDE3A-SLFN12 complex inducer (WO2019025562A1; example 135)[1].

[Related Catalog]:

Research Areas >> Cancer

Signaling Pathways >> Metabolic Enzyme/Protease >> Phosphodiesterase (PDE)

[Target]

PDE3A:87 nM (IC50)

PDE3B:50 nM (IC50)

[In Vitro]

BAY 2666605 (example 135) has anticancer effects, potently inhibit brain cancer(especially glioma, more specifically glioblastoma, astrocytoma), breast cancer (especially ductal carcinoma and adenocarcinoma), cervical cancer, AML(especially erythroleucemia), lung cancer(especially NSCLC adenocarcinoma and SCLC), skin cancer(especially melanoma), oesophagus cancer (especially squamous cell carcinoma), ovarian cancer, (especially teratocarcinoma, adenocarcinoma), pancreas cancer and prostatic cancer[1].

[In Vivo]

BAY 2666605 (5 mg/kg; p.o; twice daily) teatment shows anti-tumor efficacy in murine xenotransplantation models of human cancer[1].

[References]

[1]. Manuel ELLERMANN, et al. Dihydrooxadiazinones. WO2019025562A1.

Chemical & Physical Properties

[ Molecular Formula ]:
C₁₇H₁₂F₄N₂O₂

[ Molecular Weight ]:
352.28

BAY 2666605

Names

Biological Activity

Chemical & Physical Properties

Related Compounds